Cohort study reveals prognostic factors affecting survival and treatment response in neurolymphomatosis patients.
Key Points
Improved progression-free survival seen with primary neurolymphomatosis and preserved performance status, while CNS involvement worsens outcomes.
Kaplan-Meier methods used to assess survival in 149 patients, revealing median progression-free survival of 13 months and overall survival of 56 months.
Autologous stem cell transplant associated with better outcomes; frontline therapies were primarily methotrexate and bendamustine based.
Findings underline the need for standard management approaches in neurolymphomatosis and highlight challenges in treatment due to disease burden.